← All trials
NCT07182682
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Oct 31, 2025
- Primary completion
- Sep 30, 2029
- Completion date
- Jan 31, 2031
- First posted
- Sep 19, 2025
- Last posted
- Sep 19, 2025
- Enrollment
- 360
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Dizal (Jiangsu) Pharmaceutical Co., Ltd.Lead sponsor
- Tianjin Medical UniversityOfficial
- Huazhong University of Science and TechnologyOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.